|
1
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Board PG and Menon D: Glutathione
transferases, regulators of cellular metabolism and physiology.
Biochim Biophys Acta. 1830:3267–3288. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singh S: Cytoprotective and regulatory
functions of glutathione S-transferases in cancer cell
proliferation and cell death. Cancer Chemother Pharmacol. 75:1–15.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clapper ML and Szarka CE: Glutathione
S-transferases-biomarkers of cancer risk and chemopreventive
response. Chem Biol Interact. 111:377–388. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mahajan S and Atkins WM: The chemistry and
biology of inhibitors and pro-drugs targeted to glutathione
S-transferases. Cell Mol Life Sci. 62:1221–1233. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sau A, Pellizzari Tregno F, Valentino F,
Federici G and Caccuri AM: Glutathione transferases and development
of new principles to overcome drug resistance. Arch Biochem
Biophys. 500:116–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ruzza P and Calderan A: Glutathione
transferase (GST)-activated prodrugs. Pharmaceutics. 5:220–231.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johansson K, Ito M, Schophuizen CM, Mathew
Thengumtharayil S, Heuser VD, Zhang J, Shimoji M, Vahter M, Ang WH,
et al: Characterization of new potential anticancer drugs designed
to overcome glutathione transferase mediated resistance. Mol Pharm.
8:1698–1708. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ertan-Bolelli T, Musdal Y, Bolelli K,
Yilmaz S, Aksoy Y, Yildiz L, Aki-Yalcin E and Yalcin I: Synthesis
and biological evaluation of
2-substituted-5-(4-nitrophenylsulfonamido) benzoxazoles as human
GST P1-1 inhibitors, and description of the binding site features.
Chem Med Chem. 9:984–992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koehler RT, Villar HO, Bauer KE and
Higgins DL: Ligand-based protein alignment and isozyme specificity
of glutathione S-transferase inhibitors. Proteins. 28:202–216.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morgan AS, Ciaccio PJ, Tew KD and Kauvar
LM: Isozyme-specific glutathione S-transferase inhibitors
potentiate drug sensitivity in cultured human tumor cell lines.
Cancer Chemother Pharmacol. 37:363–370. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mohana K and Achary A: Human cytosolic
Glutathione-S-transferases: Quantitative analysis of expression,
comparative analysis of structures and inhibition strategies of
isozymes involved in drug resistance. Drug Metab Rev. 49:318–337.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tew KD, Monks A, Barone L, Rosser D,
Akerman G, Montali JA, Wheatley JB and Schmidt DE Jr:
Glutathione-associated enzymes in the human cell lines of the
National Cancer Institute Drug Screening Program. Mol Pharmacol.
50:149–159. 1996.PubMed/NCBI
|
|
15
|
Lin C, Xie L, Lu Y, Hu Z and Chang J:
miR-133b reverses cisplatin resistance by targeting GSTP1 in
cisplatin-resistant lung cancer cells. Int J Mol Med. 41:2050–2058.
2018.PubMed/NCBI
|
|
16
|
Liu H, Yang Z, Zang L, Wang G, Zhou S, Jin
G, Yang Z and Pan X: Downregulation of Glutathione S-transferase A1
suppressed tumor growth and induced cell apoptosis in A549 cell
line. Oncol Lett. 16:467–474. 2018.PubMed/NCBI
|
|
17
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moscow JA and Dixon KH:
Glutathione-related enzymes, glutathione and multidrug resistance.
Cytotechnology. 12:155–170. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Y and Zhu Z, Cai H, Liu Q, Zhou H and
Zhu Z: SKI-II reverses the chemoresistance of SGC7901/DDP gastric
cancer cells. Oncol Lett. 8:367–373. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Z, Xie Z, Sun G, Yang P, Li J, Yang
H, Xiao S, Liu Y, Qiu H, Qin L, et al: Reversing drug resistance of
cisplatin by hsp90 inhibitors in human ovarian cancer cells. Int J
Clin Exp Med. 8:6687–6701. 2015.PubMed/NCBI
|
|
22
|
Ye LY, Hu S, Xu HE, Xu RR, Kong H, Zeng
XN, Xie WP and Wang H: The effect of tetrandrine combined with
cisplatin on proliferation and apoptosis of A549/DDP cells and A549
cells. Cancer Cell Int. 17:402017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang W, Liu F, Wang C, Wang C, Tang Y and
Jiang Z: Glutathione S-transferase A1 mediates nicotine-induced
lung cancer cell metastasis by promoting epithelial-mesenchymal
transition. Exp Ther Med. 14:1783–1788. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bradford MA: Rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Habig WH, Pabst MJ and Jakoby WB:
Glutathione S-transferases: The first enzymatic step in mercapturic
acid formation. J Biol Chem. 249:7130–7139. 1974.PubMed/NCBI
|
|
26
|
Mansoori B, Mohammadi A, Davudian S,
Shirjang S and Baradaran B: The different mechanisms of cancer drug
resistance: A brief review. Adv Pharm Bull. 7:339–348. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Allocati N, Masulli M, Di Ilio C and
Federici L: Glutathione transferases: Substrates, inihibitors and
pro-drugs in cancer and neurodegenerative diseases. Oncogenesis.
7:82018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Singhal SS, Singh SP, Singhal P, Horne D,
Singhal J and Awasthi S: Antioxidant role of glutathione
S-transferases: 4-Hydroxynonenal, a key molecule in stress-mediated
signaling. Toxicol Appl Pharmacol. 289:361–370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rudd LP, Kabler SL, Morrow CS and Townsend
AJ: Enhanced glutathione depletion, protein adduct formation, and
cytotoxicity following exposure to 4-hydroxy-2-nonenal (HNE) in
cells expressing human multidrug resistance protein-1 (MRP1)
together with human glutathione S-transferase-M1 (GSTM1). Chem Biol
Interact. 194:113–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Li Y, Chen W, Wang Y, Hui L, Liu
J, Li N, Zhang L, Zou Y and Wang F: Nrf-2/Gst-α mediated imatinib
resistance through rapid 4-HNE clearance. Exp Cell Res. 353:72–78.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pajaud J, Kumar S, Rauch C, Morel F and
Aninat C: Regulation of signal transduction by glutathione
transferases. Int J Hepatol. 2012:1376762012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ricci G, De Maria F, Antonini G, Turella
P, Bullo A, Stella L, Filomeni G, Federici G and Caccuri AM:
7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide
inhibitors for glutathione S-transferases. Mechanism of action of
potential anticancer drugs. J Biol Chem. 280:26397–26405. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Turella P, Cerella C, Filomeni G, Bullo A,
De Maria F, Ghibelli L, Ciriolo MR, Cianfriglia M, Mattei M,
Federici G, et al: Proapoptotic activity of new glutathione
S-transferase inhibitors. Cancer Res. 65:3751–3761. 2005.
View Article : Google Scholar : PubMed/NCBI
|
